Revenue
2010
2011
2022
2023
2024
2025
Daxor Corp (DXR)
Price$10.50Cached quote
Net income
2010
2011
2022
2023
2024
2025
Free cash flow
2010
2011
Total cash / debt
CashTotal debt
2010
2011
2021
2022
2023
2024
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2011 | 2010 | |
|---|---|---|---|---|---|---|
| Revenue | $10.3M | $2.1M | $1.3M | $6.3M | $1.4M | $1.6M |
| Gross profit | — | — | — | — | $793,834 | $851,607 |
| Gross margin | — | — | — | — | 54.89% | 53.92% |
| Research & development | — | — | — | — | $2.7M | $3.0M |
| Operating expenses | $1.1M | $1.6M | $999,875 | $1.1M | $6.6M | $6.5M |
| Operating income | — | — | — | — | −$5.8M | −$5.7M |
| Operating margin | — | — | — | — | −400.07% | −358.34% |
| EBITDA | — | — | — | — | −$5.5M | −$5.4M |
| EBITDA margin | — | — | — | — | −379.97% | −339.56% |
| Net income | $9.2M | $536,334 | $280,640 | $5.2M | −$7.2M | $5.0M |
| Net profit margin | 89.00% | 25.17% | 21.92% | 82.06% | −496.81% | 314.60% |
| Basic EPSper basic share | $1.64 | -$0.09 | $0.14 | $0.87 | -$1.70 | $1.17 |
| Diluted EPSper diluted share | $1.64 | -$0.09 | $0.14 | $0.87 | -$1.70 | $1.17 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Feldschuh Michael Richard | 243.69K |
THOMPSON SIEGEL & WALMSLEY LLC | 241.77K |
Feldschuh Jonathan Adam | 78.91K |
VANGUARD CAPITAL MANAGEMENT LLC | 48.83K |
Aristides Capital LLC | 41.69K |
Michel Robert J | 33.05K |
RENAISSANCE TECHNOLOGIES LLC | 29.42K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 27.13K |
Jefferies John | 23.56K |
NANO CAP NEW MILLENNIUM GROWTH FUND L P | 12.5K |
Crescent Grove Advisors, LLC | 12.42K |
SBI Securities Co., Ltd. | 3.13K |
MORGAN STANLEY | 3.09K |
VANGUARD FIDUCIARY TRUST CO | 1.04K |
OSAIC HOLDINGS, INC. | 500 |
Tower Research Capital LLC (TRC) | 305 |
UBS Group AG | 172 |
JPMORGAN CHASE & CO | 6 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 8, 2026Form 4 | Feldschuh Michael RichardChief Executive Officer | BuyDaxor Common Stock | 1.0K | $9.07 | $9.1K | 213.7K |
| Mar 31, 2026Form 4 | Michel Robert JChief Financial Officer | BuyDaxor Common Stock | 1.0K | $9.90 | $9.9K | 21.1K |
| Mar 20, 2026Form 4 | Jefferies JohnChief Medical Officer | BuyDaxor Common Stock | 2.3K | $0.00 | $0.00 | 23.6K |
| Mar 20, 2026Form 4 | Jefferies JohnChief Medical Officer | BuyDaxor Common Stock | 3.7K | $0.00 | $0.00 | 21.3K |
| Dec 9, 2025Form 4 | Michel Robert JChief Financial Officer | BuyDaxor Common Stock | 3.0K | $0.00 | $0.00 | 20.1K |